PAK4 inhibition improves PD-1 blockade immunotherapy.

PAK4 inhibition improves PD-1 blockade immunotherapy.
复制标题

DOI:
10.1038/s43018-019-0003-0
复制
发表时间:
2020
期刊:
影响因子:
22.7
通讯作者:
Ribas A
Ribas A
中科院分区:
医学1区
文献类型:
--
作者:
Abril-Rodriguez G;Torrejon DY;Liu W;Zaretsky JM;Nowicki TS;Tsoi J;Puig-Saus C;Baselga-Carretero I;Medina E;Quist MJ;Garcia AJ;Senapedis W;Baloglu E;Kalbasi A;Cheung-Lau G;Berent-Maoz B;Comin-Anduix B;Hu-Lieskovan S;Wang CY;Grasso CS;Ribas A

文献摘要

参考文献

被引文献

相似文献

免疫细胞缺乏对肿瘤的浸润是癌症对程序性细胞死亡蛋白1(PD-1)阻断疗法产生原发性耐药的主要机制。据推测,癌细胞内在机制可能会主动将T细胞排斥在肿瘤之外,这表明找到可被抑制以增加T细胞浸润的可作用分子,可能会与免疫检查点抑制剂疗法产生协同作用。在此,我们发现p21激活激酶4(PAK4)在T细胞和树突状细胞浸润较少、对治疗无反应的肿瘤活检样本中富集。在小鼠模型中,PAK4基因缺失以CD8 T细胞依赖的方式增加了T细胞浸润,并逆转了对PD-1阻断的耐药性。此外,与单独使用抗PD-1药物相比,抗PD-1药物与PAK4抑制剂KPT-9274联合使用可增强抗肿瘤反应。因此,PAK4高表达与T细胞和树突状细胞浸润较少以及对PD-1阻断治疗无反应相关,而这种情况可通过抑制PAK4来逆转。
Lack of tumor infiltration by immune cells is the main mechanism of primary resistance to programmed cell death protein 1 (PD-1) blockade therapies for cancer. It has been postulated that cancer cell-intrinsic mechanisms may actively exclude T cells from tumors, suggesting that the finding of actionable molecules that could be inhibited to increase T cell infiltration may synergize with checkpoint inhibitor immunotherapy. Here, we show that p21-activated kinase 4 (PAK4) is enriched in non-responding tumor biopsies with low T cell and dendritic cell infiltration. In mouse models, genetic deletion of PAK4 increased T cell infiltration and reversed resistance to PD-1 blockade in a CD8 T cell-dependent manner. Furthermore, combination of anti-PD-1 with the PAK4 inhibitor KPT-9274 improved anti-tumor response compared with anti-PD-1 alone. Therefore, high PAK4 expression is correlated with low T cell and dendritic cell infiltration and a lack of response to PD-1 blockade, which could be reversed with PAK4 inhibition.
人角蛋白:生物学和病理学。
DOI: 10.1007/s00418-008-0435-6
发表时间: 2008-06
影响因子: 2.3
作者:
Moll, Roland;Divo, Markus;Langbein, Lutz
通讯作者: Langbein, Lutz
DOI: 10.1371/journal.pcbi.1005112
发表时间: 2016-09
影响因子: 4.3
作者:
Chen H;Lau MC;Wong MT;Newell EW;Poidinger M;Chen J
通讯作者: Chen J
DOI: 10.1158/2159-8290.cd-15-1545
发表时间: 2016-08
期刊: Cancer discovery
影响因子: 28.2
作者:
Chen PL;Roh W;Reuben A;Cooper ZA;Spencer CN;Prieto PA;Miller JP;Bassett RL;Gopalakrishnan V;Wani K;De Macedo MP;Austin-Breneman JL;Jiang H;Chang Q;Reddy SM;Chen WS;Tetzlaff MT;Broaddus RJ;Davies MA;Gershenwald JE;Haydu L;Lazar AJ;Patel SP;Hwu P;Hwu WJ;Diab A;Glitza IC;Woodman SE;Vence LM;Wistuba II;Amaria RN;Kwong LN;Prieto V;Davis RE;Ma W;Overwijk WW;Sharpe AH;Hu J;Futreal PA;Blando J;Sharma P;Allison JP;Chin L;Wargo JA
通讯作者: Wargo JA
DOI: 10.1016/j.celrep.2013.11.037
发表时间: 2013-12-26
期刊: Cell reports
影响因子: 8.8
作者:
Li J;Chen X;Ding X;Cheng Y;Zhao B;Lai ZC;Al Hezaimi K;Hakem R;Guan KL;Wang CY
通讯作者: Wang CY
DOI: 10.1093/bioinformatics/btu638
发表时间: 2015-01-15
期刊: Bioinformatics (Oxford, England)
影响因子: --
作者:
Anders S;Pyl PT;Huber W
通讯作者: Huber W